NASDAQ:TORC - resTORbio Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding resTORbio, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $1.52 +0.06 (+4.11 %) (As of 02/24/2020 04:40 AM ET) Add Compare Today's Range$1.44Now: $1.52▼$1.5550-Day Range$1.28MA: $1.44▼$1.7052-Week Range$0.94Now: $1.52▼$11.96Volume1.63 million shsAverage Volume1.24 million shsMarket Capitalization$55.39 millionP/E RatioN/ADividend YieldN/ABeta2.58 ProfileAnalyst RatingsAdvanced ChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email resTORbio, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of aging-related diseases. Its lead program is targeting the selective inhibition of TORC1, an evolutionary conserved pathway that contributes to the decline in function of multiple organ systems, including the immune, cardiac, and neurologic systems. Read More… Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:TORC Previous Symbol CUSIPN/A CIK1720580 Webhttp://www.restorbio.com/ Phone857-315-5528Debt Debt-to-Equity RatioN/A Current Ratio9.95 Quick Ratio9.95Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$3.71 per share Price / Book0.41Profitability EPS (Most Recent Fiscal Year)($1.42) Net Income$-37,610,000.00 Net MarginsN/A Return on Equity-49.53% Return on Assets-46.42%Miscellaneous EmployeesN/A Outstanding Shares36,440,000Market Cap$55.39 million Next Earnings Date3/16/2020 (Estimated) OptionableNot Optionable Receive TORC News and Ratings via Email Sign-up to receive the latest news and ratings for TORC and its competitors with MarketBeat's FREE daily newsletter. NASDAQ:TORC Rates by TradingView resTORbio (NASDAQ:TORC) Frequently Asked Questions What is resTORbio's stock symbol? resTORbio trades on the NASDAQ under the ticker symbol "TORC." How were resTORbio's earnings last quarter? resTORbio, Inc. (NASDAQ:TORC) issued its quarterly earnings data on Tuesday, November, 5th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.54) by $0.14. View resTORbio's Earnings History. When is resTORbio's next earnings date? resTORbio is scheduled to release their next quarterly earnings announcement on Monday, March 16th 2020. View Earnings Estimates for resTORbio. What price target have analysts set for TORC? 4 analysts have issued twelve-month target prices for resTORbio's stock. Their forecasts range from $3.00 to $28.00. On average, they anticipate resTORbio's share price to reach $15.50 in the next twelve months. This suggests a possible upside of 919.7% from the stock's current price. View Analyst Price Targets for resTORbio. What is the consensus analysts' recommendation for resTORbio? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for resTORbio in the last year. There are currently 4 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for resTORbio. Has resTORbio been receiving favorable news coverage? Media headlines about TORC stock have trended positive recently, InfoTrie Sentiment Analysis reports. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores nearest to five being the most favorable. resTORbio earned a media sentiment score of 3.0 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, indicating that recent press coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for resTORbio. Are investors shorting resTORbio? resTORbio saw a increase in short interest in the month of January. As of January 31st, there was short interest totalling 1,860,000 shares, an increase of 50.0% from the January 15th total of 1,240,000 shares. Based on an average trading volume of 2,060,000 shares, the days-to-cover ratio is presently 0.9 days. Approximately 6.7% of the shares of the stock are sold short. View resTORbio's Current Options Chain. Who are some of resTORbio's key competitors? Some companies that are related to resTORbio include Agile Therapeutics (AGRX), Arbutus Biopharma (ABUS), Cerecor (CERC), Affimed (AFMD), Theratechnologies (THTX), Abeona Therapeutics (ABEO), Kezar Life Sciences (KZR), Nature's Sunshine Products (NATR), Athersys (ATHX), Five Prime Therapeutics (FPRX), Scpharmaceuticals (SCPH), Fortress Biotech (FBIO), Evelo Biosciences (EVLO), TAIWAN LIPOSOME/S (TLC) and Chiasma (CHMA). What other stocks do shareholders of resTORbio own? Based on aggregate information from My MarketBeat watchlists, some companies that other resTORbio investors own include Novavax (NVAX), Denali Therapeutics (DNLI), SCYNEXIS (SCYX), Spectrum Pharmaceuticals (SPPI), Viking Therapeutics (VKTX), Abeona Therapeutics (ABEO), Catalyst Pharmaceuticals (CPRX), Crispr Therapeutics (CRSP), Cytokinetics (CYTK) and Editas Medicine (EDIT). Who are resTORbio's key executives? resTORbio's management team includes the folowing people: Mr. Chen Schor, Co-Founder, Pres, CEO & Director (Age 47)Dr. Joan Mannick M.D., Co-Founder & Chief Medical Officer (Age 60)Mr. John J. McCabe CPA, CPA, VP of Fin. (Age 51)Ms. Jennifer Robinson, Sr. Director of Investor Relations & Corp. CommunicationDr. Abdellah Sentissi Ph.D., Head of CMC & Pharmaceutical Devel. (Age 69) When did resTORbio IPO? (TORC) raised $86 million in an initial public offering on Friday, January 26th 2018. The company issued 5,700,000 shares at $14.00-$16.00 per share. BofA Merrill Lynch, Leerink Partners and Evercore ISI acted as the underwriters for the IPO and Wedbush PacGrow was co-manager. Who are resTORbio's major shareholders? resTORbio's stock is owned by a variety of of retail and institutional investors. Top institutional investors include UBS Group AG (1.69%), Acadian Asset Management LLC (1.26%), State Street Corp (0.94%), Geode Capital Management LLC (0.92%), Ruffer LLP (0.82%) and Charles Schwab Investment Management Inc. (0.24%). Company insiders that own resTORbio stock include Chen Schor and Puretech Health Llc. View Institutional Ownership Trends for resTORbio. Which major investors are selling resTORbio stock? TORC stock was sold by a variety of institutional investors in the last quarter, including Charles Schwab Investment Management Inc. and Oxford Asset Management LLP. View Insider Buying and Selling for resTORbio. Which major investors are buying resTORbio stock? TORC stock was bought by a variety of institutional investors in the last quarter, including UBS Group AG, Acadian Asset Management LLC, Ruffer LLP, Geode Capital Management LLC, State Street Corp, Goldman Sachs Group Inc. and Brave Asset Management Inc.. View Insider Buying and Selling for resTORbio. How do I buy shares of resTORbio? Shares of TORC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab. What is resTORbio's stock price today? One share of TORC stock can currently be purchased for approximately $1.52. How big of a company is resTORbio? resTORbio has a market capitalization of $55.39 million. The company earns $-37,610,000.00 in net income (profit) each year or ($1.42) on an earnings per share basis. View Additional Information About resTORbio. What is resTORbio's official website? The official website for resTORbio is http://www.restorbio.com/. How can I contact resTORbio? resTORbio's mailing address is 500 BOYLSTON STREET 13TH FLOOR, BOSTON MA, 02116. The company can be reached via phone at 857-315-5528. MarketBeat Community Rating for resTORbio (NASDAQ TORC)Community Ranking: 2.5 out of 5 ( )Outperform Votes: 127 (Vote Outperform)Underperform Votes: 124 (Vote Underperform)Total Votes: 251MarketBeat's community ratings are surveys of what our community members think about resTORbio and other stocks. Vote "Outperform" if you believe TORC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe TORC will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/24/2020 by MarketBeat.com StaffFeatured Article: Are sell-side analysts objective?
